Literature DB >> 7943309

Use of a leucine clamp to demonstrate that IGF-I actively stimulates protein synthesis in normal humans.

D L Russell-Jones1, A M Umpleby, T R Hennessy, S B Bowes, F Shojaee-Moradie, K D Hopkins, N C Jackson, J M Kelly, R H Jones, P H Sönksen.   

Abstract

Insulin-like growth factor I (IGF-I) is thought to mediate the anabolic action of growth hormone. A glucose and amino acid clamp technique was used to investigate the effects of a 3-h intravenous infusion of either 43.7 pmol.kg-1.min-1 (20 micrograms.kg-1.h-1) IGF-I or 3.4 pmol.kg-1.min-1 (0.5 mU.kg-1.min-1) insulin on whole body leucine turnover in five normal human volunteers. During the IGF-I infusion, IGF-I levels increased (P < 0.01; 26.6 +/- 2.8 to 88.9 +/- 14.2 nmol/l) and insulin levels fell (P < 0.05; 0.096 +/- 0.018 to 0.043 +/- 0.009 nmol/l). During the insulin infusion, insulin levels increased (P < 0.01; 0.057 +/- 0.013 to 0.340 +/- 0.099 nmol/l), and there was no change in IGF-I. There was no significant change in leucine production rate (Ra; a measure of protein degradation) during the IGF-I infusion (2.23 +/- 0.17 to 2.13 +/- 0.2 mumol.kg-1.min-1), but there was an increase (P < 0.03) in nonoxidative leucine disposal rate (Rd; a measure of protein synthesis; 1.83 +/- 0.15 to 2.05 +/- 0.21 mumol.kg-1.min-1). In contrast, insulin reduced (P < 0.02) leucine Ra (1.81 +/- 0.24 to 1.47 +/- 0.24 mumol.kg-1.min-1) and had no effect on nonoxidative leucine Rd (1.44 +/- 0.25 to 1.41 +/- 0.22 mumol.kg-1.min-1). We conclude that IGF-I, under conditions of adequate substrate supply, directly increases protein synthesis in contrast to insulin, which exerts its anabolic action by reducing proteolysis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7943309     DOI: 10.1152/ajpendo.1994.267.4.E591

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  16 in total

1.  GH/IGF-I axis in severe systemic disorders.

Authors:  P De Feo
Journal:  J Endocrinol Invest       Date:  2002-06       Impact factor: 4.256

Review 2.  Hormone replacement therapy and physical function in healthy older men. Time to talk hormones?

Authors:  Manthos G Giannoulis; Finbarr C Martin; K Sreekumaran Nair; A Margot Umpleby; Peter Sonksen
Journal:  Endocr Rev       Date:  2012-03-20       Impact factor: 19.871

Review 3.  Growth hormone and sport: abuse, potential benefits, and difficulties in detection.

Authors:  M L Healy; D Russell-Jones
Journal:  Br J Sports Med       Date:  1997-12       Impact factor: 13.800

4.  Effects of growth hormone and insulin-like growth factor-1 on postoperative muscle and substrate metabolism.

Authors:  Folke Hammarqvist; Ingmar Wennström; Jan Wernerman
Journal:  J Nutr Metab       Date:  2009-11-22

5.  Enhancement of muscle mitochondrial function by growth hormone.

Authors:  Kevin R Short; Niels Moller; Maureen L Bigelow; Jill Coenen-Schimke; K Sreekumaran Nair
Journal:  J Clin Endocrinol Metab       Date:  2007-11-13       Impact factor: 5.958

Review 6.  Effects of GH and insulin-like growth factor-I on body composition.

Authors:  J Svensson; L Lönn; G Johannsson; B A Bengtsson
Journal:  J Endocrinol Invest       Date:  2003-09       Impact factor: 4.256

Review 7.  Growth hormone, IGF-I and insulin and their abuse in sport.

Authors:  R I G Holt; P H Sönksen
Journal:  Br J Pharmacol       Date:  2008-03-31       Impact factor: 8.739

8.  Insulin and insulin-like growth factor-I enhance human skeletal muscle protein anabolism during hyperaminoacidemia by different mechanisms.

Authors:  D A Fryburg; L A Jahn; S A Hill; D M Oliveras; E J Barrett
Journal:  J Clin Invest       Date:  1995-10       Impact factor: 14.808

9.  Effect of a LoBAG30 diet on protein metabolism in men with type 2 diabetes. A Randomized Controlled Trial.

Authors:  Frank Q Nuttall; Mary C Gannon
Journal:  Nutr Metab (Lond)       Date:  2012-05-20       Impact factor: 4.169

Review 10.  Could Exogenous Insulin Ameliorate the Metabolic Dysfunction Induced by Glucocorticoids and COVID-19?

Authors:  Martin Brunel Whyte; Prashanth R J Vas; Anne M Umpleby
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-18       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.